Pioglitazone ( DrugBank: Pioglitazone )


17 diseases
告示番号疾患名(ページ内リンク)臨床試験数
2筋萎縮性側索硬化症3
6パーキンソン病1
13多発性硬化症/視神経脊髄炎2
15封入体筋炎1
20副腎白質ジストロフィー2
46悪性関節リウマチ4
49全身性エリテマトーデス1
65原発性免疫不全症候群2
67多発性嚢胞腎1
78下垂体前葉機能低下症1
81先天性副腎皮質酵素欠損症1
86肺動脈性肺高血圧症1
96クローン病1
229肺胞蛋白症(自己免疫性又は先天性)1
265脂肪萎縮症6
298遺伝性膵炎1
299嚢胞性線維症3

2. 筋萎縮性側索硬化症


臨床試験数 : 645 薬物数 : 589 - (DrugBank : 163) / 標的遺伝子数 : 150 - 標的パスウェイ数 : 225
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
1NCT00919555
(ClinicalTrials.gov)
June 20088/6/2009Combination Therapy in Amyotrophic Lateral Sclerosis (ALS)Phase IIA Trial: Tretinoin and Pioglitazone HCL Combination Therapy in Amyotrophic Lateral SclerosisAmyotrophic Lateral SclerosisDrug: Pioglitazone and Tretinoin;Drug: Tretinoin and Pioglitazone HCL;Drug: PlaceboPhoenix Neurological Associates, LTDNULLCompleted18 Years85 YearsBoth28Phase 1/Phase 2United States
2NCT00690118
(ClinicalTrials.gov)
May 20082/6/2008Study of Pioglitazone in Patients With Amyotrophic Lateral SclerosisEfficacy, Safety and Tolerability Study of 45 mg Pioglitazone in Patients With Amyotrophic Lateral Sclerosis (ALS) Receiving Standard Therapy (Riluzole)Amyotrophic Lateral SclerosisDrug: pioglitazone;Drug: placeboUniversity of UlmNULLTerminated18 YearsN/ABoth219Phase 2Germany;Italy
3EUCTR2006-005410-13-DE
(EUCTR)
22/04/200821/01/2008EFFICACY, SAFETY AND TOLERABILITY STUDY OF 45 mg PIOGLITAZONE IN PATIENTS WITH AMYOTROPHIC LATERAL SCLEROSIS (ALS) RECEIVING STANDARD THERAPY (RILUZOLE).EFFICACY, SAFETY AND TOLERABILITY STUDY OF 45 mg PIOGLITAZONE IN PATIENTS WITH AMYOTROPHIC LATERAL SCLEROSIS (ALS) RECEIVING STANDARD THERAPY (RILUZOLE). Male or female adult patients with amyotrophic lateral sclerosis (ALS) accoring to the El Escorial Criteria for the diognosis of ALS and treated for at least 3 month with 100 mg riluzole (standard therapy).
MedDRA version: 9.1;Level: LLT;Classification code 10002026;Term: Amyotrophic lateral sclerosis
Trade Name: Actos 15 mg
INN or Proposed INN: Pioglitazone
Trade Name: Actos 30 mg
INN or Proposed INN: Pioglitazone
Trade Name: Actos 45 mg
INN or Proposed INN: Pioglitazone
University Hospital of UlmNULLNot RecruitingFemale: yes
Male: yes
Germany

6. パーキンソン病


臨床試験数 : 2,307 薬物数 : 2,007 - (DrugBank : 349) / 標的遺伝子数 : 188 - 標的パスウェイ数 : 199
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
1NCT01280123
(ClinicalTrials.gov)
March 20113/12/2010Pioglitazone in Early Parkinson's DiseaseA Multi-Center, Double-Blind, Placebo-Controlled Phase II Study of Pioglitazone in Early Parkinson's DiseaseParkinson's DiseaseDrug: Pioglitazone;Drug: placeboUniversity of RochesterNational Institute of Neurological Disorders and Stroke (NINDS);Michael J. Fox Foundation for Parkinson's ResearchCompleted30 YearsN/AAll210Phase 2United States

13. 多発性硬化症/視神経脊髄炎


臨床試験数 : 3,340 薬物数 : 2,163 - (DrugBank : 383) / 標的遺伝子数 : 241 - 標的パスウェイ数 : 238
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
1NCT03109288
(ClinicalTrials.gov)
August 11, 201711/4/2017Targeting Residual Activity By Precision, Biomarker-Guided Combination Therapies of Multiple Sclerosis (TRAP-MS)Targeting Residual Activity By Precision, Biomarker-Guided Combination Therapies of Multiple Sclerosis (TRAP-MS)Multiple SclerosisDrug: Pioglitazone;Drug: clemastine fumarate;Drug: Dantrolene;Drug: PirfenidoneNational Institute of Allergy and Infectious Diseases (NIAID)NULLRecruiting18 YearsN/AAll250Phase 1/Phase 2United States
2NCT00242177
(ClinicalTrials.gov)
October 200318/10/2005Pilot Test of ACTOS in Multiple Sclerosis: Safety and TolerabilityPilot Test of ACTOS in Multiple Sclerosis: Safety and TolerabilityMultiple Sclerosis, Relapsing-RemittingDrug: ACTOS (Pioglitazone)University of Illinois at ChicagoTakeda Pharmaceuticals North America, Inc.Completed18 Years65 YearsAll30Phase 1United States

15. 封入体筋炎


臨床試験数 : 42 薬物数 : 33 - (DrugBank : 11) / 標的遺伝子数 : 12 - 標的パスウェイ数 : 123
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
1NCT03440034
(ClinicalTrials.gov)
May 22, 201814/11/2017Study of Pioglitazone in Sporadic Inclusion Body MyositisAn Open-Label Pilot Study of Pioglitazone in Sporadic Inclusion Body MyositisMyositis;Inclusion Body Myositis;Muscular Diseases;Musculoskeletal Disease;Neuromuscular Diseases;Nervous System DiseasesDrug: PioglitazoneJohns Hopkins UniversityNULLCompleted50 YearsN/AAll19Phase 1United States

20. 副腎白質ジストロフィー


臨床試験数 : 61 薬物数 : 90 - (DrugBank : 31) / 標的遺伝子数 : 23 - 標的パスウェイ数 : 126
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
1NCT03864523
(ClinicalTrials.gov)
January 201616/9/2016Effect of Pioglitazone Administered to Patients With AdrenomyeloneuropathyEffect of Pioglitazone Administered to Patients With Adrenomyeloneuropathy: a Phase II, Single-arm, Multicentric Clinical TrialAdrenomyeloneuropathy;X-linked AdrenoleukodystrophyDrug: PioglitazoneOnofre, Aurora Pujol, M.D.Instituto de Salud Carlos III;Fundacion Hesperia;ELA España AssociationCompleted18 Years65 YearsAll18Phase 2Spain
2EUCTR2011-006113-34-ES
(EUCTR)
24/10/201312/09/2013Effect of pioglitazone in patienst with Adrenomyeloneuropathy.Effect of pioglitazone administred to patients with Adrenomyeloneuropathy: A phase II, Singlearm, Monocentric Trial. - Pioglitazone in Adrenomyeloneuropathy X-linked adrenoleukodystrophy;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]INN or Proposed INN: PIOGLITAZONEAURORA PUJOL ONOFRENULLAuthorised-recruitment may be ongoing or finishedFemale: yes
Male: yes
Phase 2Spain

46. 悪性関節リウマチ


臨床試験数 : 4,356 薬物数 : 2,567 - (DrugBank : 415) / 標的遺伝子数 : 192 - 標的パスウェイ数 : 228
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
1NCT02535832
(ClinicalTrials.gov)
September 201524/8/2015Skeletal Muscle Dysfunction in Rheumatoid Arthritis (RA)Skeletal Muscle Dysfunction in Rheumatoid Arthritis (RA)Rheumatoid Arthritis;Insulin ResistanceDrug: Pioglitazone;Drug: PlaceboOhio State UniversityNULLRecruiting35 Years65 YearsAll36Phase 1United States
2NCT01309854
(ClinicalTrials.gov)
March 201121/2/2011Effects of Administration of Fostamatinib on Blood Concentrations of Pioglitazone in Healthy SubjectsAn Open-Label, Single Center Study to Assess the Pharmacokinetics of Pioglitazone in Healthy Subjects When Administered Alone and in Combination With Fostamatinib 100 mg Twice DailyRheumatoid Arthritis;Healthy Volunteers;Pharmacokinetics;Pioglitazone;Drug-drug Interaction;Amount of Pioglitazone in BloodDrug: fostamatinib;Drug: pioglitazoneAstraZenecaNULLCompleted18 Years55 YearsBoth15Phase 1United States
3NCT00763139
(ClinicalTrials.gov)
April 200926/9/2008Inflammation and Insulin Resistance in Rheumatoid ArthritisInflammation and Insulin Resistance in Rheumatoid ArthritisRheumatoid ArthritisDrug: Pioglitazone;Drug: PlaceboVanderbilt UniversityNational Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)Completed18 YearsN/AAll34N/AUnited States
4NCT00554853
(ClinicalTrials.gov)
November 20076/11/2007PPAR-gamma Agonists, Rheumatoid Arthritis and Cardiovascular DiseasePeroxisome Proliferator-activated Receptor-gamma Agonists, Rheumatoid Arthritis and Cardiovascular DiseaseRheumatoid ArthritisDrug: pioglitazone;Drug: Sublingual nitroglycerineUniversity of MichiganNational Heart, Lung, and Blood Institute (NHLBI)Completed21 Years100 YearsAll143Phase 3United States

49. 全身性エリテマトーデス


臨床試験数 : 993 薬物数 : 702 - (DrugBank : 184) / 標的遺伝子数 : 116 - 標的パスウェイ数 : 200
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
1NCT01322308
(ClinicalTrials.gov)
March 200723/3/2011Effect of Pioglitazone on Endothelial Function in Premenopausal Women With Uncomplicated Systemic Lupus ErythematosusEffect of Pioglitazone on Endothelial Function in Premenopausal Women With Uncomplicated Systemic Lupus Erythematosus, a Randomized, Double-blind, Placebo-controlled Clinical TrialSystemic Lupus ErythematosusDrug: pioglitazone;Drug: placeboNational Heart Institute, MexicoNational Council of Science and Technology, Mexico;Universidad Nacional Autonoma de MexicoCompleted18 Years55 YearsFemale30Phase 4NULL

65. 原発性免疫不全症候群


臨床試験数 : 500 薬物数 : 614 - (DrugBank : 119) / 標的遺伝子数 : 92 - 標的パスウェイ数 : 217
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
1NCT03080480
(ClinicalTrials.gov)
September 1, 201727/2/2017Pioglitazone Therapy for Chronic Granulomatous DiseaseEfficacy and Safety of Pioglitazone Therapy for Chronic Granulomatous Disease Patients With Severe Infection.Chronic Granulomatous DiseaseDrug: PioglitazoneChildren's Hospital of Fudan UniversityNULLTerminated1 Month18 YearsAll3Phase 1/Phase 2China
2NCT02733679
(ClinicalTrials.gov)
September 29, 201631/3/2016Response of Individuals With Ataxia-Telangiectasia to Metformin and PioglitazoneResponse of Individuals With Ataxia-Telangiectasia to Metformin and PioglitazoneAtaxia-TelangiectasiaDrug: Metformin;Drug: PioglitazoneNHS TaysideUniversity of DundeeCompleted18 Years30 YearsAll27Phase 4United Kingdom

67. 多発性嚢胞腎


臨床試験数 : 221 薬物数 : 212 - (DrugBank : 55) / 標的遺伝子数 : 40 - 標的パスウェイ数 : 151
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
1NCT02697617
(ClinicalTrials.gov)
January 26, 201630/10/2015Use of Low Dose Pioglitazone to Treat Autosomal Dominant Polycystic Kidney DiseaseUse of Low Dose Pioglitazone to Treat Autosomal Dominant Polycystic KidneyPolycystic Kidney DiseaseDrug: Pioglitazone;Drug: PlaceboIndiana UniversityNULLActive, not recruiting18 Years55 YearsAll18Phase 2United States

78. 下垂体前葉機能低下症


臨床試験数 : 492 薬物数 : 341 - (DrugBank : 47) / 標的遺伝子数 : 45 - 標的パスウェイ数 : 100
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
1NCT00459940
(ClinicalTrials.gov)
September 200412/4/2007The Effects of TZD on Fat Metabolism and Insulin Sensitivity in GH-Replaced GHD PatientsCan Growth Hormone's Lipolytic and Insulin-Antagonistic Effects be Modified by Peroxisome Proliferator-Activated Gamma Agonists?Growth Hormone DeficiencyDrug: PioglitazoneUniversity of AarhusNULLCompleted19 Years71 YearsMale20N/ADenmark

81. 先天性副腎皮質酵素欠損症


臨床試験数 : 87 薬物数 : 87 - (DrugBank : 23) / 標的遺伝子数 : 12 - 標的パスウェイ数 : 68
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
1NCT00151710
(ClinicalTrials.gov)
May 20058/9/2005Effects of Pioglitazone in Congenital Adrenal HyperplasiaEffects of Pioglitazone in Glucocorticoid-Induced Insulin Resistance. Studies in Congenital Adrenal Hyperplasia.Congenital Adrenal HyperplasiaDrug: PioglitazoneRadboud UniversityNULLCompleted18 YearsN/ABothN/ANetherlands

86. 肺動脈性肺高血圧症


臨床試験数 : 1,205 薬物数 : 684 - (DrugBank : 124) / 標的遺伝子数 : 100 - 標的パスウェイ数 : 193
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
1NCT00825266
(ClinicalTrials.gov)
September 200816/1/2009Insulin Resistance in Pulmonary Arterial HypertensionThe Effect of Bosentan and Pioglitazone on Insulin Resistance in Pulmonary Arterial HypertensionHypertension, PulmonaryDrug: bosentan;Drug: PioglitazoneStanford UniversityNULLTerminated18 Years75 YearsAll2Phase 2United States

96. クローン病


臨床試験数 : 2,442 薬物数 : 1,278 - (DrugBank : 248) / 標的遺伝子数 : 142 - 標的パスウェイ数 : 209
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
1NCT01489943
(ClinicalTrials.gov)
September 19, 20111/12/2011A Study to Investigate the Effect of GSK1605786 on Hepatic Cytochrome P450, and BCRP and OATP1B1 Transport in Healthy Adult SubjectsA Single Centre, Single Sequence, Open-Label, Repeat-Dose Study to Investigate the Effect of GSK1605786 on Hepatic Cytochrome P450, and BCRP and OATP1B1 Transport in Healthy Adult SubjectsCrohn's DiseaseDrug: GSK1605786 500 mg;Drug: Midazolam 3 mg;Drug: Pioglitazone 15 mg;Drug: Omeprazole 40 mg;Drug: Rosuvastatin 10 mgGlaxoSmithKlineNULLCompleted18 Years55 YearsAll24Phase 1United States

229. 肺胞蛋白症(自己免疫性又は先天性)


臨床試験数 : 44 薬物数 : 22 - (DrugBank : 7) / 標的遺伝子数 : 3 - 標的パスウェイ数 : 14
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
1NCT03231033
(ClinicalTrials.gov)
August 17, 201719/6/2017Pioglitazone Therapy of Autoimmune Pulmonary Alveolar Proteinosis Autoimmune Pulmonary Alveolar ProteinosisFirst in Human Study of Pioglitazone Therapy of Autoimmune Pulmonary Alveolar ProteinosisAutoimmune Pulmonary Alveolar ProteinosisDrug: PioglitazoneChildren's Hospital Medical Center, CincinnatiNULLCompleted18 Years80 YearsAll3Phase 1United States

265. 脂肪萎縮症


臨床試験数 : 112 薬物数 : 155 - (DrugBank : 55) / 標的遺伝子数 : 25 - 標的パスウェイ数 : 97
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
1NCT01612858
(ClinicalTrials.gov)
June 20114/6/2012Metabolic Abnormalities in HIV-infected PersonsMetabolic Abnormalities in HIV-infected PersonsLipodystrophy;HIV InfectionDrug: Metformin;Drug: PioglitazoneTufts Medical CenterNational Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)Completed18 Years70 YearsAll20Phase 4United States
2NCT01023620
(ClinicalTrials.gov)
October 200930/11/2009HIV Acquired Lipodystrophy (HAL) Classification, Measurement and Fat Response to Thiazolidinedione (TZD) (Pioglitazone)Human Immunodeficiency Virus Acquired Lipodystrophy (HAL) Classification, Measurement, & Fat Response to a Thiazolidinedione (TZD) Challenge in Differing Adult Phenotypic PresentationsHIV InfectionsDrug: Pioglitazone;Other: ObservationUniversity of Texas Southwestern Medical CenterTakeda Pharmaceuticals North America, Inc.Completed18 YearsN/AMale4N/AUnited States
3NCT00362440
(ClinicalTrials.gov)
August 20069/8/2006Combination of Insulin Sensitizer and Leptin as Treatment for the HAART -Induced Metabolic SyndromeA Combination of Insulin Sensitizer and Leptin as Treatment for the HAART -Induced Metabolic Syndrome: A Randomized, Double-blind, Placebo-controlled Clinical TrialHIV LipodystrophyDrug: Leptin;Drug: Pioglitazone or metformin;Drug: PlaceboBeth Israel Deaconess Medical CenterAmerican Diabetes AssociationCompleted18 YearsN/AAll9Phase 2United States
4NCT00656851
(ClinicalTrials.gov)
September 200510/4/2008Myocardial Function & FFA Metabolism in HIV Metabolic SyndromeMyocardial Function, Free Fatty Acid and Glucose Metabolism in HIV Metabolic SyndromeHIV Infections;Cardiovascular Disease;Insulin Resistance;HIV Lipodystrophy;The Metabolic SyndromeDrug: Pioglitazone;Behavioral: Exercise TrainingNational Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)NULLCompleted28 Years50 YearsAll24N/AUnited States
5NCT00639457
(ClinicalTrials.gov)
January 200518/3/2008Exercise and Pioglitazone for HIV-Metabolic SyndromesExercise and Pioglitazone for HIV-Metabolic SyndromesHIV Infections;Type 2 Diabetes;Obesity;HIV;AIDS;Cardiovascular Disease;LipodystrophyDrug: Pioglitazone;Behavioral: Exercise trainingNational Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)NULLCompleted18 Years65 YearsAll44N/AUnited States
6NCT00148850
(ClinicalTrials.gov)
February 20037/9/2005Effect of Pioglitazone on HIV-1 Related Lipoatrophy: a Randomized, Double Blind, Placebo-Controlled Trial in 130 PatientsA Randomized, Phase 3, Double Blind, Multicentre Trial, Evaluating the Effect of Pioglitazone Versus Placebo on Change in Lipoatrophy in HIV- 1 Infected Patients Treated With Stable Antiretroviral Therapy for at Least 6 Months.ANRS 113 LIPIOT StudyHIV-Associated Lipodystrophy Syndrome;HIV InfectionsDrug: PioglitazoneFrench National Agency for Research on AIDS and Viral HepatitisTakedaTerminated18 YearsN/ABoth130Phase 3France

298. 遺伝性膵炎


臨床試験数 : 95 薬物数 : 148 - (DrugBank : 51) / 標的遺伝子数 : 53 - 標的パスウェイ数 : 142
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
1NCT00782795
(ClinicalTrials.gov)
November 200829/10/2008Chronic Pancreatitis. Effect of Pioglitazone on Endocrine Function, Exocrine Function & Structure, Pain & Life QualityPhase II Study of Chronic Pancreatitis and the Effect of Pioglitazone on Endocrine Function, Exocrine Function & Structure, Pain & Life QualityChronic Pancreatitis;Insulin Resistance;Normal or Mildly Abnormal Stool Fat LevelsDrug: Pioglitazone;Drug: PlaceboUniversity of MichiganNational Institute on Alcohol Abuse and Alcoholism (NIAAA);Takeda Pharmaceuticals North America, Inc.Completed18 Years75 YearsAll64Phase 2United States

299. 嚢胞性線維症


臨床試験数 : 1,695 薬物数 : 1,527 - (DrugBank : 268) / 標的遺伝子数 : 111 - 標的パスウェイ数 : 174
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
1NCT00719381
(ClinicalTrials.gov)
January 200817/7/2008Effect of Pioglitazone on Inflammation in Cystic FibrosisEffect of Pioglitazone on Sputum Biomarkers of Inflammation and Lung Epithelial Repair in Cystic FibrosisCystic FibrosisDrug: PioglitazonePaul BeringerNULLCompleted18 YearsN/ABoth24Phase 1United States
2NCT00531882
(ClinicalTrials.gov)
September 200718/9/2007Pilot Mouthwash Study of Pioglitazone and Simvastatin in Healthy VolunteersA Pilot Study Evaluating the Effect of Pioglitazone, Simvastatin, and Ibuprofen on Neutrophil Migration in Vivo in Healthy SubjectsCystic FibrosisDrug: Pioglitazone;Drug: Simvastatin;Drug: IbuprofenUniversity Hospitals Cleveland Medical CenterNULLCompleted18 Years50 YearsAll25N/AUnited States
3NCT00322868
(ClinicalTrials.gov)
April 20064/5/2006Safety and Efficacy of Pioglitazone as an Anti-inflammatory for the Treatment of Cystic Fibrosis (CF) Lung DiseaseA Pilot Study Assessing the Safety and Efficacy of Pioglitazone as an Anti-inflammatory Agent for the Treatment of CF Lung Disease in Patients With Cystic FibrosisCystic FibrosisDrug: pioglitazoneUniversity Hospitals Cleveland Medical CenterCystic Fibrosis FoundationCompleted18 YearsN/AAll21N/AUnited States